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(57) ABSTRACT 
Disclosed are nanoparticles having a metallic core consisting 
essentially of superparamagnetic iron oxide; a polymeric coat 
surrounding said core, the coat having a matrix of polyacrylic 
acid and forming an outer periphery of said nanoparticle; a 
plurality of hydrophobic pockets formed by the polymeric 
coat; a plurality of carboxylic groups along an outer periphery 
of the polymeric coat and effective to conjugate with a pre-
determined targeting ligand which functionalizes the nano-
particle; a lipophylic fluorescent dye encapsulated in the plu-
rality of hydrophobic pockets; and a drug encapsulated in the 
plurality of hydrophobic pockets. Associated methods of 
making the nanoparticles and of treatments using the nano-
particles are also disclosed. 
26 Claims, 15 Drawing Sheets 
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MULTIMODAL, MULTIFUNCTIONAL 
POLYMER COATED NANOPARTICLES 
RELATED APPLICATION 
This application claims priority from co-pending provi-
sional application Ser. No. 61/041,613, which was filed on 2 
Apr. 2008, and to provisional application Ser. No. 61/161, 
476, which was filed on 19 Mar. 2009 and is incorporated 
herein by reference in its entirety. 
STATEMENT OF GOVERNMENT RIGHTS 
Development of the present invention was supported, at 
least in part, by a grant from the U.S. Government. Accord-
ingly, the Government may have certain rights in the inven-
tion, as specified by law. 
FIELD OF THE INVENTION 
The present invention relates to the field of medical treat-
ment of disease and, more particularly, to multimodal, mul-
tifunctional nanoparticles which serve as drug carriers for 
targeted delivery and which can also be tracked by optical and 
magnetic resonance imaging. 
BACKGROUND OF THE INVENTION 
2 
capabilities and ( e) a superparamagnetic iron oxide core for 
magnetic resonance imaging (MRI). 
Biocompatible, multimodal and theranostically functional 
IONPs were synthesized using a novel water-based method 
5 and demonstrated excellent properties for targeted cancer 
therapy, optical and magnetic resonance imaging (MRI). For 
the first time, a facile, modified solvent diffusion method is 
used for the co-encapsulation of both an anti-cancer drug and 
near infrared fluorescent dyes. The resulting folate-deriva-
10 tized theranostic nanoparticles could allow for targeted opti-
cal/MR-imaging and targeted killing of folate expressing 
cancer cells. 
Specifically, our synthetic procedure differs from the pre-
viously reported methods in that the polymer is not present 
during the initial nucleation process.[6-8] Instead, the poly-
15 acrylic acid is added at a later stage. This "step-wise" process, 
as opposed to the "in-situ" process, allows for the formation 
of stable, dispersed and highly crystalline superparamagnetic 
ironoxidenanocrystals coated with PAA, (step 1, as shown in 
FIG. 1). Successful coating with PAA was confirmed by the 
20 presence of a negative zeta-potential g=-48 m V) and via 
FT-IR analysis (as shown in FIG. 8). We then hypothesized 
whether a hydrophobic dye could be encapsulated within the 
hydrophobic pockets in the PAA coating, to thereby generate 
multimodal IONPs with dual magnetic and fluorescent prop-
25 erties. As a proof-of-principle, we have encapsulated two 
lipophilic fluorescent dyes (DiI or DiR) (step 2, as shown in 
FIG. 1) using a modified solvent diffusion method.[9] These 
dialkylcarbocyanine fluorophores (DiI, DiR) are widely used 
in biomedical applications to label cell membranes and were 
selected because of their high extinction coefficients ( c> 125, 
30 000 cm- 1 M- 1) and high fluorescence in hydrophobic envi-
ronments.[9] The long chain dialkylcarbocyanine dye, DiR, 
is of particular importance since it has an excitation/emission 
near the infrared region (751/780), suitable for in vivo imag-
Superparamagnetic iron oxide nanoparticles with dual 
imaging and therapeutic capabilities hold great promise for 
the non-invasive detection and treatment oftumors.[1] When 
conjugated with tumor-specific targeting ligands, these mul-
tifunctional nanoparticles can be used to specifically deliver 
anti-cancer drugs to tumors, thereby minimizing severe side 
effects.[2] To meet the demand for the rapid development and 35 
potential clinical application of targeted anti-cancer nano-
therapies, it is desirable to introduce optical (fluorescent) 
imaging capabilities to these nanoparticles to facilitate non-
invasive assessment of drug homing and efficacy. This is often 
achieved by crosslinking the polymeric coating surrounding 
the nanoparticle and functionalizing its surface with amine or 
carboxyl groups that are then used to conjugate fluorescent 
dyes and drugs. [3] This approach to introduce multimodality 
(magnetic and fluorescent)[4] and multifunctionality (imag-
ing and therapeutic)[5] to iron oxide nanoparticles (IONPs), 
although widely used, often compromises the solubility of the 
nanoparticles in aqueous media and reduces the number of 
available functional groups that otherwise could be used to 
attach ligands for targeting applications. 
ing. 
Next, the IONPs (1, FIG. 1) were functionalized to yield a 
propargylated nanoparticles (3, FIG. 1), which were later 
used to generate multimodal folate-derivatized nanoparticles 
(4, FIG. 1) via a highly selective 1,3-dipolar cycloaddition 
reaction ("click" chemistry).[10] Thus, the water-soluble car-
40 bodiimide EDC, [1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide hydrochloride] was utilized to prepare the propargy-
lated IONP (3, FIG.1), which is an important synthonforthe 
synthesis of a library offunctional IONPs via "click" chem-
istry. Thepresenceofa weak 'C C'bandat2265 cm- 1 in the 
45 FT-IR spectrum of these nanoparticles confirmed the pres-
ence of a propargyl (triple bond) group (FIG. 9). 
As a model system, we conjugated the nanoparticles 3 with 
an azide-functionalized folic acid[l 1] analog (FIG. 6) via 
"click" chemistry. The resulting folate-decorated IONPs are 
soluble in aqueous media and can encapsulate lipophilic fluo-
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides iron oxide nanoparticles (IONPs) wherein 
a lipophilic near infrared (NIR) dye and an anti-cancer drug 
are co-encapsulated within hydrophobic pockets formed in a 
polymeric matrix of polyacrylic acid (PAA) which coats the 
nanoparticles (PAA-IONPs). The resulting composition is 
useful for combined optical imaging, MRI detection and tar-
geted cancer therapy. 
Our water-based and green chemistry approach to synthe-
sizing these nanoparticles has five components (a) an encap-
sulated chemotherapeutic agent effective in cancer therapy 
(for example, paclitaxel, also known by the tradename Taxol), 
50 rescent dyes. The presence of folic acid and dye in these 
multimodal folate-derivatized nanoparticles ( 4, Scheme 1) 
was confirmed through various spectrophotometric studies 
(FIGS. 10-12). Furthermore, a hydrophobic anti-cancer drug 
(paclitaxel, a.k.a. Taxol®) was encapsulated to yield a thera-
55 nostic (therapeutic and diagnostic) nanoparticle with dual 
imaging and therapeutic properties (5, Scheme 1). These 
functional IONPs (1-5) were highly stable in aqueous solu-
tions, as their magnetic relaxivity (R2), hydrodynamic diam-
eter (D) and polydispersity index (PDI) remained unaffected 
60 over a long period of time (Table 3). Therefore, the versatility 
of the present method allows the generation of a small library 
of multifunctional, multimodal and targetable IONPs. 
BRIEF DESCRIPTION OF THE DRAWINGS 
(b) a surface functionality (folic acid ligand) for cancer tar- 65 
geting, (c) "click"-chemistry-based conjugation of targeting 
ligands, ( d) an encapsulated NIR fluorescent dye for imaging 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
US 8,236,284 B 1 
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apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 is a schematic representation of the synthesis of 5 
theranostics andmultimodal IONPs according to an embodi-
ment of the present invention; click chemistry and carbodi-
imide chemistry have been used for the synthesis of a library 
of functional IONPs; NIR dyes and paclitaxel coencapsulated 
IONPs were prepared in water using the modified solvent 10 
diffusion method detailed below; 
FIG. 2 shows the characterization of multimodal nanopar-
ticles 2 (PAA-IONP-DiI);A) determination ofhydrodynamic 
diameter of the IONPs through Dynamic Light Scattering 
15 
(DLS), Inset: Transmission Electron Microscope (TEM) 
image of the corresponding nanoparticles (scale bar 100 nm.); 
B) magnetic hysteresis loops at 300 and 5 K, showing nano-
particles are superparamagnetic; C) fluorescence emission 
spectra (in PBS buffer) ofDiI dye encapsulated IONPs 2 and 20 
that of 1 without any dye; D) fluorescence emission spectra of 
2 and that of free non-encapsulated DiI in solution; 
FIG. 3 shows a determination of cytotoxicity of the func-
tional IONPs: carboxylated [COOH (2)], propargylated 
[PROPARGYL (3)], folate-conjugated [FOLATE (4)] and 25 
Taxol-carrying [TAXOL (5)]; control (CTRL) cells: A) Lung 
carcinoma cells (A549) and B) Cardiomyocyte cells (H9c2) 
were treated with PBS; average values of four measurements 
are depicted±standard error; 
FIG. 4 depicts an assessment ofIONPs' cellular uptake via 30 
confocal laser-scamiing microscopy using lung carcinoma 
A549 cells;A) no internalization was observed in cells treated 
with carboxylated IONPs (2), as no DiI fluorescence was 
observed in the cytoplasm; B) enhanced internalization was 
observed upon incubation with the folate-immobilized 35 
IONPs ( 4); C) Taxol® and DiI co-encapsulated folate-func-
tionalized IONPs (5) induced cell death; (D-F) corresponding 
merged confocal images of the functional IONPs treated cells 
with their nucleus stained with DAPI (blue); 
FIG. 5 shows drug and dye release profiles of functional 40 
IONPs (5) in PBS (pH=7.4) at 37° C.; release ofTaxol® (A& 
B) and DiI (C & D) was observed in the presence of an 
esterase enzyme (A & C) and at pH 4.0 (B & D); 
FIG. 6 illustrates synthesis of folate conjugated PAA-
IONPs using carbodiimide chemistry and "click" chemistry; 45 
FIG. 7 shows a High Resolution Transmission Electron 
Microscope (HR-TEM) image of the polyacrylic acid coated 
iron oxide nanoparticles (PAA-IONPs, 2); scale bar 300 nm; 
FIG. 8 is an FT-IR spectroscopic analysis of the synthe-
sized IONPs (1, PAA-IONP, red line) and polyacrylic acid 50 
(PAA, black line); presence of the band at 1685 cm- 1 in 1 
confirms the presence of a PAA coating in the IONPs; 
FIG. 9 are FT-IR spectra of propargylated nanoparticles (3, 
IONP-PAA-C2, black line) and carboxylated IONP (1, 
IONP-PAA, red line); presence of a weak band at 2265 cm- 1 55 
confirms the presence of propargyl groups in IONPs 3; 
FIG.10 shows spectrophotometric characterizations of the 
folate-conjugated PAA-IONPs (3a); a) UVNis spectrum of 
3a showing absorbance at 352 nm, indicating the presence of 
folic acid on the iron oxide nanoparticles; b) fluorescence 60 
emission spectrum (a.u.) of 3a showing the characteristic 
fluorescent emission at 441 nm and confirming the presence 
offolic acid on the nanoparticles; 
FIG. 11 depicts UV/Vis spectra of a) DiI encapsulated 
IONPs (2) and b) corresponding DiR encapsulated IONPs 65 
(2-DiR) showing the presence of encapsulated DiI (555 nm) 
and DiR (754 nm) inside the PAA coating ofIONPs; 
4 
FIG. 12 presents spectrophotometric characterizations of 
the DiI encapsulated folate clicked IONPs (4); a) UVNis 
spectrum showing absorbance at 352 nm and 555 nm indicat-
ing the presence of folic acid and DiI dye, respectively; b) 
Fluorescence emission spectrum (a.u.) showing intensity 
maximum at 441 nm and 581 nm confirmed for the "click" 
chemistry with folic acid and effective encapsulation of DiI 
dye; similar results were obtained for paclitaxel and DiI 
encapsulated folate conjugated IONPs; 
FIG. 13 provides fluorescence emission spectra (a.u.) 
showing intensity maximum at 445 nm for Taxol® encapsu-
lated IONPs (5) and 375 nm for free Taxol®, confirming the 
presence of the drug inside the PAA polymer coating of the 
iron oxide nanoparticles; 
FIG. 14 depicts epifluorescence images of A) live and B) 
fixed lung carcinoma cells (A549) after incubation of folate-
decorated IONPs (4) for 3 h; cell internalization (A549) and 
cytoplasmic localization is observed either in live or fixed 
cells; similar results were observed in the case of non-cancer-
ous cell (cardiomyocytes) lines; nucleus stained with DAPI 
(blue color); 
FIG. 15 shows confocal images of a) lung carcinomaA549 
cells pre-incubated (saturated, no free folate receptor) with 
free folic acid (100 µL, 10 mg/mL) and then incubated with 
folate-IONPs (4, 50 µL, 1.1 mg/mL) and free folic acid (50 
µL, 10 mg/mL ); b) cardiomyocyte cells (H9c2, no folate 
receptor) incubated with folate-IONPs ( 4, 50 µL, 1.1 
mg/mL); no internalization was observed due to absence of 
free folate receptors (a, A549) or absence offolate receptors 
(b, H9c2); these observations confirmed the targeting capa-
bility and receptor mediated endocytosis of our theranostic 
IONPs; cells incubated for 3 h with functional IONPs 4 and 
the nuclei were stained with DAPI (blue); 
FIG. 16 shows NIR fluorescence imaging of lung carci-
noma cells (A549) incubated with (A) carboxylated IONPs 
(2-DiR) or (B) folate conjugated IONPs ( 4-DiR); images 
were taken using an ICG filter; 
FIG. 17 is a dual image of DiI and DiR wherein (A) is a 
composite fluorescence optical image of 4-DiI and 4-DiR, 
taken in separate tubes, showing the imaging capability of the 
both IONPs; fluorescence images were taken by scanning the 
entire wavelength from 480 to 920 nm and performing spec-
tral unmixing; (B) Dual image of DiI and DiR using the 
MAESTRO optical imager; it shows the combined image as 
an overlay of both images in the lower row (D and E); WL 
indicates the White Light image; DiI was obtained at 595 nm 
and DiR at 780 nm; and 
FIG. 18 is an MR image (T2 map) of a PAA-IONP 4 
encapsulating either DiI or DiR ( 4-DiI or 4-DiR); these MR 
images were obtained by making dilutions from a stock (100 
µg/mL) nanoparticle suspension and comparing their MRI 
signal with that of water; the color bar indicates the T2 relax-
ation time in ms. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
US 8,236,284 B 1 
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tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 5 
Accordingly, this invention may be embodied in different 
forms and should not be construed as limited to the illustrated 
embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 10 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Materials and Methods: 
Iron salts: FeC12 .4H2 0 and FeCl3 .6H20, animonium 15 
hydroxide, hydrochloric acid, folic acid, DMF, 3-(4,5-Dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
esterase (from porcine liver, 16.5 mg protein/mL of Biuret, 
177 units/mg of protein), N-hydroxysuccinimide (NHS), 
polyacrylic acid and other chemicals were purchased from 20 
Sigma-Aldrich. Dialky lcarbocyanine fluorescent dyes (DiI-
D282 and DiR-D12731) and 4', 6-diamidino-2-phenylin-
dole (DAPI-D1306) were purchased from Invitrogen, EDC 
(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydro-
chloride) was obtained from Pierce Biotechnology. The 25 
human lung carcinoma A549 (CCL-185) and cardiomyocyte 
(H9c2) cell lines were obtained from ATCC. Dialysis mem-
branes were obtained from Spectrum Laboratories. Nitrogen 
purged DI water was used in the synthesis. 
Instrumentation: Infrared spectra were recorded on a 30 
PerkinElmer Spectrum 100 FT-IR spectrometer. UV/Vis 
spectra were recorded using CARY 300 Bio UV Nis spectro-
photometer. Fluorescence spectra were recorded on a 
NanoLog Horiba Jobin Yvon spectrophotometer. NMR spec-
trum was recorded on a MERCURY 300 MHz spectrometer 35 
using the TMS/solvent signal as an internal reference. 
Dynamic light scattering (DLS) studies were done using a 
PDDLS/Coo!Batch 40T instrument using Precision Decon-
volve 32 software. High throughput absorbance readings for 
MTT assays were done using a BIO-TEK Synergy HT multi- 40 
detection microplate reader. The core size and morphology of 
the nanoparticles were characterized by using high resolution 
transmission electron microscopy (HRTEM, FEI Technai 
F30). Overall surface charge (zeta potential) of IONP was 
measured using Zetasizer Nano ZS from Malvern Instru- 45 
ments. Transverse (T2) proton relaxation times measure-
ments were done using a Bruker Minispec mq20 NMR ana-
lyzer operating at a magnetic field of 0.47 T and at 37° C. 
Fluorescent images of nanoparticles in solution were per-
formed using a Maestro CIRL optical imaging scarmer. Mag- 50 
netic resonance images of nanoparticles in solution were 









The scheme for synthesis of azido-folic acid (7) from chlo-
ropropyl amine is shown above. 
Synthesis of Aminopropylazide (6): In a 100 mL round 
bottom flask, chloropropyl amine (7.0 g, 75.26 mmol) and 
sodium azide (14 .23 g, 225. 81 mmol) were added to 40 mL of 
distilled water and heated at 80° C. for 20 h. The reaction 
mixture was concentrated in a rotary evaporator at high 
vacuum, 2 g of KOH were added and the product was 
extracted using diethyl ether. 
Subsequently, the reaction mixture was dried over anhy-
drous sodium sulphate and concentrated. Finally, the product 
was purified via flash column chromatography using 4% 
ethyl acetate in petrolium ether as an eluant. Yield: 5.1 g 
(68%). 1H NMR (300 MHz, CDC13 , d ppm): 1.26 (bs, 2H), 
1.81 (m, 2H), 2.80 (t, 2H), 3.38 (t, 2H). FT-IR(CHC13 ): 3307, 
2941,2089, 1663, 1433, 1370, 1259, 1242, 1075, 1026,818, 
760 cm- 1 . 
Synthesis of azide-functionalized folic acid (7): To a solu-
tion offolic acid (0.05 g, 0.12 mmol) in DMSO (2 mL), EDC 
(0.021 g, 0.11 mmol) and NHS (0.013 g, 0.11 mmol) in 0.5 
mL MES buffer (pH=5.0) were added and then incubated at 
room temperature for 3 minutes. To this resulting reaction 
mixture was added drop-wise ethylenediamine (0.007 g, 0.11 
mmol) in 0.25 mL of PBS (pH=7.4) and then incubated for3 
hat room temperature. The reaction mixture was centrifuged 
and washed to remove excess starting materials. The azide-
functionalized folic acid was dissolved in 1 mL ofDMF until 
further use. Yield: 0.05 g (86%). The presence of a band at 
2097 cm- 1 in the IR spectrum and a UV absorbance shoulder 
at 354 nm confirmed the formation of azide-functionalized 
folic acid. 1H NMR ( 400 MHz, DMSO-d6, d ppm): 1.61 (m, 
2H), 1.65 (m, 2H), 1.90 (m, 2H), 2.19 (t, 2H), 2.78 (t, 2H), 
4.18 (q, lH), 4.21(d,2H), 6.62 (d, 2H), 7.59 (d, 2H), 8.58 (s, 
lH). FT-IR: 3024, 2097, 1685, 1603, 1492, 1375, 1291, 1248, 
1180, 1122, 1062, 950, 844, 755, 696 cm- 1 . 
Synthesis of PAA-IONPs (1): For the water-based, step-
wise synthesis of polyacrylic acid-coated iron oxide nanopar-
ticles (PAA-IONPs), three solutions were prepared; an iron 
salt solution [0.62 g ofFeCly6H20 and 0.32 g ofFeCl2 .4H20 
in dilute HCl solution (100 µL of12 N HCl in 2.0mL H2 0)]; 
an alkaline solution [1.8 mL of30% NH4 0H solution in 15 
mL ofN2 purged DI water]; and a stabilizing agent solution 
[820 mg ofpolyacrylic acid in 5 mL of DI water]. To synthe-
size the PAA-IONP, the iron salt solution was added to the 
alkaline solution under vigorous stirring. The resulting dark 
suspension of iron oxide nanoparticles was stirred for 
Synthesis of Azide-Functionalized Folic Acid (7, 
Folate-N3) by Carbodiimide Chemistry 
55 approximately 30 seconds before addition of the stabilizing 
agent solution and stirred for 1 h. The resulting suspension of 
PAA-I ONPs was then centrifuged at 4000 rpm for 30 minutes 





Formula 1 60 
get rid of free polyacrylic acid and other unreacted reagents 
using an Amicon 8200 cell (Millipore ultra-filtration mem-
brane YM-30 k). Finally, the PAA-IONP suspension was 
purified using magnetic column, washed with phosphate 
buffer saline (pH=7.4) and concentrated using the Amicon 
8200 cell system. The iron concentration and magnetic relax-
65 ation of the PAA-IONPs was determined as previously 
reported [Josephson et. al. Bioconjugate Chem 1999, 10, 
186-191]. The successful coating of the IONPs with PAA was 
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confirmed by the presence of a negative zeta-potential (s=-48 
mV) and the characteristic acid carbonyl bands on the FT-IR 
spectroscopic analysis of the nanoparticles (FIGS. 6 and 8). 
Synthesis of propargylated IONPs (3): Carbodiimide 
chemistry. To a suspension of PAA-IONP (1) (45 mg Fe) in 5 
MES buffer (26 mL, pH=6), a solution of EDC (87 mg, 10 
mmol) and NHS (52 mg, 10 mmol) in MES buffer (2 mL) was 
added and incubated for 3 minutes. To the resulting reaction 
mixture, propargylamine (25mg, lOmmol)inDMF (0.5 mL) 
was added drop-wise and incubated for 5 hat room tempera- 10 
ture. The resulting reaction mixture was then purified using 
magnetic colunm and then using amicon 8200 cell (Millipore 
ultra-filtration membrane YM-30 k) to get rid of unreacted 
propargyl chloride and other unreacted reagents and kept in 
PBS at 4° C. FT-IR data analysis (FIG. 9) confirms the 15 
completion and success of the conjugation. 
General procedure for dye-encapsulated functional IONPs 
(2, 4 ): Modified solvent diffusion method. To a suspension of 
IONPs (4.5 mL, [Fe]=l.1 mg/mL) in PBS, a solution of the 
corresponding dialkylcarbocyanine fluorescent dyes (DiI or 20 
DiR, 0.1 µg/µL) in DMF was added drop-wise at room tem-
perature with continuous stirring at 1000 rpm. The resulting 
dye-encapsulated IONPs were purified using a magnetic col-
unm and then dialyzed (using 6-8 K molecular weight cut off 
dialysis bag) three times against deionized water and finally 25 
against phosphate buffered saline solution. The successful 
encapsulation of the corresponding dye (DiI or DiR) on the 
PAA-IONPs was confirmed by UVNis spectrophotometric 
measurements (FIG. lOa-b). In addition, when these nano-
particles were functionalized with folate, the presence of both 30 
folate and dye encapsulated groups were assessed by UV /Vis 
(FIG. 12a) and fluorescence (FIG. 12b) spectrometry. 
Procedure for co-encapsulation of Paclitaxel and Oil into 
IONPs (5): A solution containing paclitaxel (5 µL, 0.05 
µg/µL) andDiI dye (5 µL, 0.1 µg/µL) in500 µLDMFwas used 35 
and the same modified solvent diffusion method was fol-
lowed as described above. The presence of Taxol® in the 
IONPs (5) was confirmed by using fluorescence spectropho-
tometer (FIG. 13). 
8 
cardiomyocyte cells (2,500 cells/well) were seeded in 
96-well plates, and were incubated with the IONPs for 3 hat 
37° C. Then, each well was washed three times with lxPBS 
and treated with20 µL MTT (5 µg/µl, 3-( 4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) for 
2 h. The resulting formazan crystals were dissolved in acidi-
fied isopropanol (0.1 N HCl) and the absorbance was 
recorded at 570 nm and 750 nm (background), using a Syn-
ergy HT multi-detection microplate reader (Biotek). These 
experiments were performed in triplicate. 
Cellular internalization: Confocal Microscopy and IVIS 
experiments. A Zeiss LSM 510 confocal and Zeiss Axiovert 
200 epifluorescence microscopes were used to assess the 
uptake offolate-derivatized IONPs by the human lung carci-
noma (A549) cell line. Specifically, A549 cells (10,000) were 
incubated with the corresponding IONPs preparation (1.1 
mg/mL) for 3 h in a humidified incubator (37° C., 5% C02). 
Subsequently, the cells were thoroughly washed three times 
with 1 xPBS and fixed with 10% formalin solution. Nuclear 
staining with DAPI was performed as recommended by the 
supplier. Then, multiple confocal images were obtained, 
achieving a representative view of the cell-IONPs interaction. 
For the IVIS analysis, 10,000 lung carcinoma cells were 
incubated for 3 h with the corresponding IONPs and the 
supernatant was collected in EppendorfTubes®. Cells were 
thoroughly washed with 1 xPBS and detached them, as stated 
above. The resulting pellets were resuspended in 1 mL culture 
media. All Eppendorf Tubes® were examined simulta-
neously on a Xenogen® IVIS system, using the ICG filter for 
DiR dye. All experiments were performed in triplicate. 
In Vitro drug/dye release: The in vitro drug/dye release 
studies were carried out using a dynamic dialysis technique at 
37° C. Briefly, 100 µL of IONPs (5) are incubated with a 
porcine liver esterase (20 µL) inside a dialysis bag (MWCO 
6000-8000), which is then placed in a PBS solution (pH 7.4). 
The amount of guest (dye or drug) molecules released from 
the nanoparticle into the PBS solution was determined at 
regular time intervals by taking 1-mL aliquots from the PBS 
solution and measuring the fluorescence intensity at 581 nm 
Synthesis of3a: Folate conjugation using Click chemistry. 40 for DiI and 375 nm for Taxol®. The concentration of the 
To a suspension of propargylated IONPs 3 (13 mg Fe) in 
bicarbonate buffer (pH=8.5), a catalytic amount ofCuI (0.06 
µg, 3x 10-10 mmol) were added for a total volume of 125 µL 
of bicarbonate buffer and vortexed for 30 seconds. Then, a 
solution of azide-functionalized folic acid (7, Formula 45 
I-above, 0.003 g, 6x10-2 mmol) in DMSO was added and 
incubated at room temperature for 12 h. The final reaction 
mixture was purified by using magnetic column and by dialy-
sis using 6-8 K molecular weight cut off dialysis bag, against 
deionized water first and a finally with a phosphate buffered 50 
saline (PBS) solution. The purified functional IONPs were 
stored at 4 ° C. until further use. The successful conjugation of 
folic acid with PAA-IONPs was confirmed by UVNis (FIG. 
lOa) and fluorescence (FIG. lOb) spectrophotometric mea-
surements. 55 
Cell culture and cell viability studies: MTT assay. The lung 
carcinoma cells (A549) and cardiomyocytes (H9c2) were 
obtained fromATCC, USA. Lung carcinomas were grown in 
Kaighn's modification of Ham's F12 medium (F12K--Cell-
gro ), supplemented with 5% fetal bovine serum (Heat-inac- 60 
tivated FBS--Cellgro ), L-glutamine, streptomycin, amphot-
ericin B, and sodium bicarbonate. The cells were maintained 
at 37° C., 5% C02 in a humidified incubator. Cardiomyocyte 
cells were grown in Eagle's Minimal Essential medium 
supplemented with 10% fetal bovine serum, sodium pyru- 65 
vate, L-glutamine, penicillin, streptomycin, amphotericin B 
and sodium bicarbonate. For MTT assay, lung carcinoma and 
either dye or drug was calculated using a standard calibration 
curve. The cumulative fraction of release versus time was 
calculated using the following equation: 
Cumulative release(%)~[guest]t/[guest]totalx100 
Where [guest ]t is the amount of guest released at time t, 
[guest]total is the total guest present in the guest encapsulated 
IONPs. 
TABLE 1 
IONPs 2 4 Time 
R1 206 ± 2 202 ± 3 207 ± 2 204 ± 3 203 ± 5 15 
D 86 90 87 94 96 Days 
(PD!) (0.89) ± (0.87) ± (0.89) ± (0.87) ± (0.91) ± 
1 2 1 3 3 
R1 206 ± 1 201±2 207 ± 3 204 ± 2 204 ±4 
D 86 91 87 94 96 Month 
(PD!) (0.89) ± (0.88) ± (0.92) ± (0.88) ± (0.90) ± 
2 3 2 3 4 
R1 208 ± 3 202 ±4 208 ± 2 203 ± 3 205 ± 5 
D 88 91 89 95 98 Months 
(PD!) (0.91) ± (0.90) ± (0.88) ± (0.91) ± (0.91) ± 
2 4 2 4 4 
R1 210 ±4 204 ±4 207 ± 3 205 ±4 208 ± 5 
D 87 92 88 96 100 Months 
(PD!) (0.95) ± (0.92) ± (0.91) ± (0.89) ± (0.88) ± 
4 5 4 4 5 
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Table 1 shows Magnetic relaxivity (R2, s31 1 mM- 1), Hydro-
dynamic diameter (D, m) and Polydispersity index (PDI) of 
all the functional iron oxide nanoparticles (IONPs) over the 
period of time, showing the stability of the functional IONPs 
(1-5) in aqueous buffered solution. 
Proof ofFolate Receptor Mediated Internalization: Confocal 
Microscopy and IVIS Experiments. 
A Zeiss LSM 510 confocal fluorescence microscope was 
used to assess the uptake offolate-derivatized IONPs by the 
human lung carcinoma (A549) cell line. Specifically, A549 
cells (10,000) were incubated with the corresponding IONPs 
preparation (1.1 mg/mL) for 3 h in a humidified incubator 
(37° C., 5% C02). 
Subsequently, the cells were thoroughly washed three 
times with 1 xPBS and fixed with 10% formalin solution. 
Nuclear staining with DAPI was performed as recommended 
by the supplier. Then, multiple confocal images were 
obtained, achieving a representative view of the cell-IONPs 
interaction (FIG. 15). 
To prove that internalization was mediated by the folate 
receptor, A549 cells were pre-incubated with free folate (to 
saturate the folate receptor) and then treated with the folate 
derivatized IONP ( 4). Results show no significant internal-
ization of the nanoparticles (FIG. 15a). Furthermore, no inter-
nalization of 4 was observed when H9c2, a cardiomyocyte 
cell line that does not express the folate receptor, was used 
(FIG. 15b). 
Fluorescence Imaging ofMultimodal Nanoparticles in Solu-
tion. 
To assess the potential application of the multimodal nano-
particles 4, in vivo, encapsulating either DiI or DiR, ( 4-DiI or 
4-DiR), a Maestro CIRL (Woburn, Mass.) was used. Further-
more, a 1: 1 mixture of the DiI and DiR nanoparticles was 
prepared and image. Results show the capability of imaging 
both nanoparticles simultaneously. 
Discussion 
Specifically, our synthetic procedure differs from the pre-
viously reported methods in that the polymer is not present 
during the initial nucleation process.[6-8] Instead, the poly-
acrylic acid is added at a later stage. This "step-wise" process, 
as opposed to the "in-situ" process, allows for the formation 
of stable, disperse and highly crystalline superparamagnetic 
ironoxidenanocrystals coated with PAA, (See 1, FIG.1). The 
successful coating with PAA was confirmed by the presence 
ofa negative zeta-potential (s=-48 m V) and via FT-IR analy-
sis (See FIG. 8). 
We then hypothesized whether a hydrophobic dye could be 
encapsulated within the hydrophobic pockets in the PAA 
coating, generating multimodal IONPs with dual magnetic 
and fluorescent properties. As a proof-of-principle, we have 
encapsulated two lipophilic fluorescent dyes (DiI or DiR) 
(See 2, FIG. 1) using a modified solvent diffusion method. [9] 
These dialkylcarbocyanine fluorophores (DiI, DiR) are 
widely used in biomedical applications to label cell mem-
branes and were selected because of their high extinction 
coefficients (c> 125,000 cm- 1 M- 1) and high fluorescence in 
hydrophobic environments.[9] The long chain dialkylcar-
bocyanine dye, DiR, is of particular importance since it has an 
excitation/emission near the infrared region (751/780), it is 
suitable for in vivo imaging. 
Next, the IONP 1 was functionalized to yield a propargy-
lated nanoparticle (See 3, FIG. 1), which was later used to 
generate a multimodal folate-derivatized nanoparticle (See 4, 
FIG. 1) via highly selective 1,3-dipolar cycloaddition reac-
tion ("click" chemistry).[10] Thus, the water-soluble carbo-
diimide EDC [11], [1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide hydrochloride] was utilized to prepare the 
10 
propargylated IONP (See 3, FIG. 1), which is an important 
synthon for the synthesis of a library of functional IONPs via 
"click" chemistry. The presence of a weak 'C C' band at 
2265 cm- 1 in the FT-IR spectrum of these nanoparticles con-
5 firmed the presence of a propargyl (triple bond) group (See 
FIG. 9). 
As a model system, we conjugated the nanoparticle 3, 
illustrated in FIG. 1, with an azide-functionalized folic acid 
analog (See also FIG. 6 and synthesis of azide-functionalized 
10 folic acid, above) via "click" chemistry. The resulting folate-
decorated IONPs are soluble in aqueous media and can 
encapsulate lipophilic fluorescent dyes. The presence of folic 
acid and dye in these multimodal folate-derivatized nanopar-
ticles (See 4, FIG. 1) was confirmed through various spectro-
15 photometric studies (See FIGS. 10-12). Furthermore, a 
hydrophobic anti-cancer drug (paclitaxel, a.k.a. Taxol®) was 
encapsulated to yield a theranostic (therapeutic and diagnos-
tic) nanoparticle with dual imaging and therapeutic properties 
(See 5, FIG. 1). These functional IONPs (1-5) were highly 
20 stable in aqueous solutions, as their magnetic relaxivity (R2), 
hydrodynamic diameter (D) and polydispersity index (PDI) 
remained unaffected over a long period of time (See Table 3). 
Therefore, the versatility of our method allows the generation 
of a small library of multifunctional, multimodal and tar-
25 getable IONPs. 
Dynamic light scattering (DLS) studies of the functional 
PAA-IONP (2) confirmed the presence of stable and mono-
dispersed nanoparticles with a hydrodynamic diameter of 90 
nm (FIG. 2A), while TEM experiments revealed an iron oxide 
30 core of 8 nm (Inset: FIG. 2A; see also FIG. 7). These mea-
surements suggest the formation of a thick polymeric coating 
(-40 nm) around the iron oxide core, which plays a key role 
in the encapsulation of hydrophobic guest molecules. FT-IR 
analysis further confirmed the presence of the PAA coating 
35 and carboxylic acid groups on 1, as well as the corresponding 
surface propargyl groups on nanoparticle 3 (See FIGS. 8-9). 
Magnetic hysteresis loops (FIG. 2B) corroborated the super-
paramagnetic nature of the nanoparticles, while water relax-
ation measurements using a 0.47T Bruker's Minispec relax-
40 ometer indicated the presence of magnetic IONPs with high 
water relaxation (Rl =53 s- 1 mM- 1 , R2=202 s- 1 mM- 1 ). The 
incorporation of a hydrophobic dye into 1 was done using a 
modified solvent diffusionmethod.[9] Specifically, a solution 
ofDiI in DMF (0.1 µg/µL) was added drop-wise to a stirring 
45 aqueous nanoparticle suspension (4.5 mL and [Fe]=l.1 
mg/mL). The slow addition of the dye solution allows forthe 
rapid diffusion ofDMF into the aqueous medium, causing the 
dye to become encapsulated in the hydrophobic micro-
domains of the PAA coating. The presence of an absorption 
50 maximum at 555 nm in the UV/Vis spectrum (See FIG. lla) 
and a corresponding fluorescence emission peak at 595 nm 
(FIG. 2C) confirmed the presence ofDiI in the nanoparticle. 
Furthermore, the encapsulation of DiI was confirmed by the 
presence of a 14 nm red-shift in the fluorescence intensity 
55 maximum of the Dil-encapsulating PAA-IONP, as compared 
to the free DiI (581 nm, FIG. 2D). Similar red-shifts have 
been previously reported in other systems, indicating an inter-
action of the fluorescent guest molecule with the electronic 
environment of the encapsulating pocket.[12] Next, we 
60 encapsulated both DiI and Taxol® to the folate-conjugated 
nanoparticle for dual cellular imaging and targeted cancer 
therapy. To synthesize such nanoparticle (5), a DMF solution 
containing DiI (0.1 µg/µL) and Taxol® (0.05 µg/µL) was 
added to a stirring solution offolate-derivatized PAA-IONPs 
65 (See compound 3a in FIG. 6). Since the dye and the drug are 
hydrophobic, we expected both molecules to become encap-
sulated. The encapsulation ofTaxol® was confirmed through 
US 8,236,284 B 1 
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These results were also observed in experiments performed 
using live (non-fixed) A54 9 cells, where internalization of the 
folate-decorated IONPs ( 4) was monitored through fluores-
cence microscopy (See FIG. 14). The enhanced cellular 
uptake of the folate-decorated nanoparticle (4) inA549 cells 
may have been attributed to folate-receptor mediated inter-
nalization. As internalization of 4 was nominal in A549 cells 
pre-incubated with free folate and in studies using the H9c2 
cardiomyocyte cell line (FIG. lS), we corroborated the recep-
fluorescence spectroscopy (FIG. 13). Furthermore, the 
amount of dye, folic acid and Taxol® molecules per nanopar-
ticle was calculated, as previously described [13] (Table 2). 
These dye-encapsulating PAA-IONPs were highly stable in 
aqueous solutions for more than a year, without significant 
reduction in the fluorescence emission of the encapsulated 
dyes. Additionally, no leaching of the encapsulated dye from 
the nanoparticle occurred, as no precipitation of the dye was 
observed after prolonged storage in PBS, pH 7.4. 
TABLE2 
Determination of magnetic relaxivity (R2), hydrodynamic diameter (D) 
and polydispersity index (PD!) of functional IONPs immediately after 
synthesis. Quantitative estimation of amount of dye, folic acid and 
Taxol ® per iron crystal of the corresponding 
multifunctional IONPs (1-5). 
10 tor-mediated internalization of our folate-decorated IONPs 
( 4). Next, we investigated the cellular uptake of a multifunc-
tional folate-conjugated nanoparticle (5) with dual imaging 
and targeted cancer therapeutic properties. When these 
IONPs were incubated with A549 cells, mitotic arrest was 
observed, leading to dramatic cellular morphological 
changes and cell death (FIGS. 4C and 4F). 
15 
R1 D (PD!) 
IONPs s- 1 mM-1 nm 
206 ± 2 86 
(0.89) ± 1 
2 202 ± 3 90 
(0.87) ± 2 
207 ± 2 87 
(0.89) ± 1 
4 204 ± 3 94 
(0.87) ± 3 
203 ± 5 96 




28 ± 2 12 ± 2 






The therapeutic application of our nanoparticles depends 
on the rate ofrelease of the encapsulated drug from the PAA 
coating. To evaluate S's drug release profile, enzymatic (es-
terase) and low-pH degradation experiments were performed. 
Results indicated a fast release of the drug (Taxol®) from the 
nanoparticle (5) upon esterase incubation, reaching a plateau 
within 2 hours (FIG. SA). An even faster release of the drug 
was observed at pH 4.0, reaching a plateau within 30 minutes 
(FIG. SB). No significant release of the drug was observed 
from nanoparticles incubated in PBS, pH 7.4. These results 
are significant as they demonstrate the stability of the nano-
particles during storage (PBS), and their cargo release only 
after cellular uptake via either esterase-mediated degradation 
To evaluate the potential biomedical applications of the 
Dil-encapsulating IONPs (2, 3, 4 and 5, 1.1 mg/mL), we 
assessed their potential cytotoxicity, via the MTT assay (FIG. 
30 or in acidified lysosomes. Therefore, only after its folate-
receptor-mediated uptake, the nanoparticle 5 becomes cyto-
toxic upon intracellular release of its cargo therapeutic agent. 
Interestingly, a much slower release of the dye was observed, 3). Therefore, we examined the in vitro differential cytotox-
icity of carboxylated (COOH, 2), propargylated (PROPAR-
GYL, 3), folate-decorated (FOLATE, 4), folate-decorated 35 
and taxol-encapsulating IONPs (TAXOL®, 5), using lung 
carcinoma (A549, 2,500 cells/well) (FIG. 2A) and cardi-
omyocyte cell lines (H9c2, 2,500 cells/well) (FIG. 2B). Car-
boxylated, propargylated and folate-conjugated IONPs 
exhibited nominal cytotoxicity (less than3% compared to the 40 
control) towards both cell lines after a 3 h incubation. On the 
other hand, incubation with the folate-decorated and taxol-
carrying IONPs ( 5) resulted in an 80% reduction in the viabil-
ity of the lung carcinoma (A549) cell line. In contrast, no 
significant reduction in cell viability was observed when car- 45 
diomyocytes (H9c2) which do not overexpress the folate 
receptor[14] were incubated with 5. These results demon-
strate that nanoparticles 1-4 were not toxic to either A549 or 
H9c2 cells, hence these nanoparticles can be used as effective 
multimodal imaging agents. However, as IONP 5 was only 50 
cytotoxic to cancer cells (A549) that overexpress folate 
receptor,[15,16] it can be utilized as a potential targeted mul-
tifunctional (imaging and therapeutic) nanoagent for the 
treatment of folate-receptor-expressing tumors. 
To further explore the potential biomedical applications of 55 
the synthesized functional PAA-IONPs, we evaluated the 
selective uptake of the folate-functionalized nanoparticle ( 4) 
by A549 lung cancer cells, as these cells overexpress the 
folate receptor. In these experiments, carboxylated (2) or 
folate-conjugated ( 4) nanoparticles (1.1 mg/mL) were incu- 60 
bated with A549 cells (10, 000 cells) for 3 h, washed to 
remove non-internalized nanoparticles and visualized via 
confocal microscopy. Results showed no internalization of 
the carboxylated nanoparticle (2) as expected (FIG. 4A, 4D). 
However, significant internalization of the folate-conjugated 65 
nanoparticle ( 4) was indicated by the presence of intense 
fluorescence in the cytoplasm of the cells (FIG. 4B, 4E). 
both upon esterase incubation and at pH 4.0 
(FIGS. SC and SD). However, no release of the dye was 
observed at normal physiological pH (7.4). The observed 
differential release of the drug vs. the dye from IONP 5 may 
be attributed to the drug's (Taxol®) size and hydrophobic 
nature. 
Taken together, these results make our folate-decorated-
IONP (5) an important drug carrier, as it can rapidly release 
Taxol® and therefore induce cell death only upon targeted 
cell internalization. Furthermore, the acidic microenviron-
ment of most tumors could enhance the release ofTaxol® and 
dye from the nanoparticle into the tumor to facilitate the 
monitoring of tumor regression by MR and optical imaging. 
Also, by modifying the targeting moiety of the theranostic 
IONP's surface, other carcinomas may be targeted, while 
obtaining important spatiotemporal information for clinical 
decision making. 
For in vivo imaging applications, nanoparticles with exci-
tation and emission in the near infrared region (650-900 nm) 
are needed for deep tissue fluorescence imaging.[ 17] Towards 
this end, we encapsulated a near infrared dialky lcarbocyanine 
dye (DiR, excitation/emission:751/780 nm) into the carboxy-
lated (2-DiR) and folate-conjugated ( 4-DiR) IONPs, follow-
ing the same synthetic protocol described for the synthesis of 
IONPs 2 and 4. UV/Vis studies corroborated the presence of 
the near infrared DiR dye within the nanoparticle's PAA 
coating (FIG. llb ). To demonstrate the targeting capability of 
our functional near-infrared and folate-derivatized IONP 
(4-DiR) to folate receptor expressing cells and eventually 
assess their intracellular activity, we incubated A549 lung 
carcinoma cells with the ( 4-DiR) nanoparticle andimaged the 
cells using fluorescence imaging techniques. 
In these studies, A549 cells (10,000 cells) were treated with 
either DiR-carrying carboxylated (2-DiR) or DiR-carrying 
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when conjugated with folic acid (using "click" chemistry) 
provide targeted drug delivery to cancer cells that overexpress 
the folate receptor, while avoiding normal cells that do not 
overexpress this receptor. We suggest that this multimodal 
(magnetic and fluorescent) and multifunctional (imaging and 
therapeutic) IONPs will open many exciting opportunities for 
the targeted delivery of therapeutic agents to tumors. In addi-
tion, the dual optical and magnetic properties of the synthe-
sized nanoparticles will allow for the dual fluorescence- and 
folate-conjugated ( 4-DiR) IONPs (1.1 mg/mL) for 3 h. Next, 
the cells were washed with PBS and detached with trypsin. 
After centrifugation, the resulting cell pellets were simulta-
neously imaged using an indocyanine green (ICG) filter. No 
cell-associated near infrared fluorescence was observed in 
cells treated with the carboxylated (2-DiR) nanoparticles 
(FIG. 16 panel A). In contrast, a dose-dependent cell-associ-
ated DiR fluorescence was observed in cells treated with the 
folate-conjugated (4-DiR) nanoparticles (FIG. 16 panel B). 
Since the cells were extensively washed with PBS before 
imaging and considering the confocal microscopy results 
shown in FIG. 4, it is plausible that the cells have internalized 
the ( 4-DiR) nanoparticles via folate-receptor-mediated 
endocytosis, thus endowing these cells with near infrared 
fluorescent. To further confirm the association of these nano-
particles with folate-expressing A549 carcinoma cells, the 
cell pellets were re-suspended in PBS and their fluorescence 
emission and MRI signal (T2 relaxation time) were recorded. 
An increase in fluorescence emission intensity and decrease 
in magnetic relaxivity (T2) was observed from the corre-
sponding suspension of the cell pellets (Table 3). No fluores-
cence emission or T2 changes were observed in H9c2 cardi-
omyocytes treated with 4-DiR. Therefore, these results 
indicate that our targeted multimodal nanoparticles can 
simultaneously allow the near infrared fluorescence and MR 
imaging of folate-receptor expressing cells. 
10 MR-based imaging and monitoring of drug efficacy. All these 
positive attributes make the functional IONPs a promising 
drug delivery vehicle for further in vivo evaluation. 
With the foregoing in mind, those skilled in the art should 
recognize that when we speak of a "metallic core" we intend 
15 a core containing a metal, in any form. Also, the skilled will 
understand that the hydrophobic pocket(s) formed by the 
polymeric coat may accept for nesting therein any dye or drug 
which is compatible with that characteristic, for example, a 
dye or drug having at least a hydrophobic or lipophilic moi-
20 ety; it is reasonable to prophetically predict that such dyes and 
drugs will also work in the invention in addition to those 
which have been disclosed herein as examples. Dyes which 
are predicted to work in the invention include, without limi-
tation, cardiogreen, quantum dots, Cy5, Cy5.5, and Alex-
TABLE3 
25 afluor dyes to mention a few. Metals which are contemplated 
to work in the invention include the following, although not 
exclusively, cerium, gold, silver, bismuth, platinum, palla-
dium and their oxides. It should also be understood that in 
addition to folate groups, amine groups and alcohol groups 
Determination of fluorescence emission intensity (a.u.) and 
magnetic relaxivity (T2) of!ONP-(4-DiR)-treated cells 
A549 in PBS. 
A549 Cell Cells Cells+ 20 Cells+ 40 Cells + 60 Cells + 80 
pellets only µLIONPs µLIONPs µL IONPs µL IONPs 
30 may also be conjugated on the nanoparticles to provide dif-
ferent targeting specificities. Regarding other drugs which are 
predicted to work in the invention, these would include anti-
HIV drugs, anti-inflammatory drugs, AzT, camptothecin, 
doxorubicin and others having hydrophobic groups. 
35 
Fl. Emission (x105 ) 0.0 1.7 2.0 2.4 2.7 
T2 (ms) 2000 165 126 101 78 
To further assess the utility of the multimodal nanoparticle 
4 encapsulating either DiI ( 4-DiI) or DiR ( 4-DiR), fluores- 40 
cence and MRI studies were performed. First, phantoms con-
taining both nanoparticles in PBS were taken using a dedi-
cated optical imaging animal scanner (Maestro, CIR, 
Woburn, Mass.). Results indicated the potential use of the 
4-DiR nanoparticle for near infrared imaging, even in a nano- 45 
particle suspension containing both 4-DiI and 4-DiR IONPs 
(FIGS. 17A-E). These results are important as they point to 
the possibility of simultaneously imaging both nanoparticles, 
which could be utilized in the imaging of two different targets 
in in vivo experiments (e.g. 2 different cell populations). 50 
Furthermore, magnetic resonance imaging (MRI) studies of 
4-DiI and 4-DiRnanoparticle dilutions (FIG.18) using a 4.7T 
MRI scanner (Bruker, Bellerica Mass.) further demonstrated 
the ability of these IONPs to behave as sensitive MRI contrast 
agents. 55 
In conclusion, we introduce a new method to synthesize 
multimodal and theranostic PAA-IONPs for the potential in 
vivo target-specific detection and treatment of tumors. Our 
novel IONPs are biocompatible and biodegradable, as they 
are synthesized from biodegradable and biocompatible com- 60 
ponents. These functional IONPs are stable in aqueous buff-
ered solutions, possess good cellular targeting ability, and 
their simple synthesis process is amenable to scale-up. In 
addition, this method can easily be used to generate libraries 
of targeted theranostic nanoparticles with different targeting 65 
ligands or encapsulated agents, and even include different 
metallic cores. Furthermore, the drug-encapsulating IONPs 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims, as set forth below. 
LITERATURE CITED 
[1] a) J. R. McCarthy, K. A. Kelly, E. Y. Sun, R. Weissleder, 
Nanomedicine 2007, 2, 153-167; b) A. K. Gupta, M. 
Gupta, Biomaterials 2005, 26, 3995-4021. 
[2] N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, J. S. 
Guthi, S. F. Chin, A. D. Sherry, D. A. Boothman, J. Gao, 
Nano Lett. 2006, 6, 2427-2430. 
[3] a) M. Lewin, N. Carlesso, C. H. Tung, X. W. Tang, D. 
Cory, D. T. Scadden, R. Weissleder, Nat. Biotechnol. 2000, 
18, 410-414; b) L. Josephson, M. F. Kircher, U. Mahmood, 
Y. Tang, R. Weissleder, Bioconjugate Chem. 2002, 13, 
554-560; c)K. C. Weng, C. 0, Noble, B. Papahadjopoulos-
Sternberg, F. F. Chen, D. C. Drummond, D. B. Kirpotin, D. 
Wang, Y. K. Hom, B. Hann, J. W. Park, Nano Lett. 2008, 8, 
2851-2857. 
[4] a) J. H. Choi, F. T. Nguyen, P. W. Barone, D.A. Heller, A. 
E. Moll, D. Patel, S. A. Boppart, M. S. Strano, Nano Lett. 
2007, 7, 861-867; b) W. J. Mulder, R. Koole, R. J. Brand-
wijk, G. Storm, P. T. Chin, G. J. Strijkers, C. de Mello 
Donega, K. Nicolay, A. W. Griffioen, Nano Lett. 2006, 6, 
1-6. 
US 8,236,284 B 1 
15 
[5] M. K.Yu, Y.Y. Jeong, J. Park, S. Park, J. W. Kim, J. J. Min, 
K. Kim, S. Jon, Angew. Chem. Int. Ed. Engl. 2008, 47, 
5362-5365. 
[6] H. Lee, M. K. Yu, S. Park, S. Moon, J. J. Min, Y. Y. Jeong, 
16 
8. The nanoparticle of claim 1, wherein folate groups are 
conjugated to a plurality of carboxylic groups on the poly-
meric coat. 
H. W. Kang, S. Jon, J. Am. Chem. Soc. 2007, 129, 12739- 5 
12745. 
9. The nanoparticle of claim 1, wherein azide-functional-
ized folate groups are conjugated to the polymeric coat. 
10. The nanoparticle of claim 1, wherein azide-functional-
ized folate groups are conjugated to the plurality of carboxy-
lic groups on the polymeric coat. 
[7] H. Lee, E. Lee, K. Kim do, N. K. Jang, Y. Y. Jeong, S. 
Jon, J. Am. Chem. Soc. 2006, 128, 7383-7389. 
[8] S. Peng, C. Wang, J. Xie, S. Sun, J. Am. Chem. Soc. 
2006, 128, 10676-10677. 
[9] a) J. R. McCarthy, J.M. Perez, C. Bruckner, R. Weissleder, 
Nano Lett. 2005, 5, 2552-2556; b) B. S. Packard, D. E. 
Wolf, Biochemistry 1985, 24, 5176-5181. 
[10] a) E. Y. Sun, L. Josephson, R. Weissleder, Molecular 
Imaging2006, 5, 122-128; b)H. C. Kolb, M. G. Finn, K. B. 
Sharpless, Angew. Chem. Int. Ed. Engl. 2001, 40, 2004-
2021; c) M.A. White, J.A. Johnson, J. T. Koberstein, N. J. 
Turro, J.Am. Chem. Soc. 2006, 128, 11356-11357. 
[11] a) S. Santra, B. Liesenfeld, D. Dutta, D. Chatel, C. D. 
Batich, W. Tan, B. M. Moudgil, R. A. Mericle, J. Nanosci. 
Nanotech. 2005, X, 1-6; b) K. Riebeseel, E. Biedermann, 
R. Lser, N. Breiter, R. Hanselmann, R. Mlhaupt, C. Unger, 
F. Kratz, Bioconjugate Chem. 2002, 13, 773-785. 
[12] M. Shi, J. H. Wosnick, K. Ho,A. Keating, M. S. Shoichet, 
Angew. Chem. Int. Ed. Engl. 2007, 46, 6126-6131. 
[13] a)A. M. Koch, F. Reynolds, M. F. Kircher, H.P. Merkle, 
R. Weissleder, L. Josephson, Bioconjugate Chem. 2003, 
14, 1115-1121; b) T. Shen, R. Weissleder, M. Papisov, A. 
Bogdanov, Jr., T. J. Brady, Magn. Reson. Med. 1993, 29, 
599-604. 
[14] N. Parker, M. J. Turk, E. Westrick, J. D. Lewis, P. S. Low, 
C. P. Leamon, Anal. Biochem. 2005, 338, 284-293. 
[15] H. Yuan, J. Miao, Y. Z. Du, J. You, F. Q. Hu, S. Zeng, Int. 
J.Pharm.2008,348, 137-145. 
11. The nanoparticle of claim 1, wherein the lipophilic 
10 fluorescent dye is selected from the group consisting of 
dialkylcarbocyanine fluorescent dyes. 
12. The nanoparticle of claim 1, wherein the lipophylic 
fluorescent dye is selected from lipophilic dyes having a 
15 
near-infrared spectrum. 
13. The nanoparticle of claim 1, wherein the lipophilic 
fluorescent dye is selected from DiI, DiR and 4',6-diamidino-
2-phenylindole. 
14. The nanoparticle of claim 1, wherein the drug com-
20 prises a hydrophobic or lipophilic moiety. 
25 
30 
15. The nanoparticle of claim 1, wherein the drug com-
prises a hydrophobic moiety. 
16. The nanoparticle of claim 1, wherein the drug is an 
anti-cancer therapeutic drug. 
17. The nanoparticle of claim 1, wherein the drug is pacli-
taxel. 
18. The nanoparticle of claim 1, wherein the lipophylic 
fluorescent dye and the drug are co-encapsulated in the plu-
rality of hydrophobic pockets. 
19. A method of treatment comprising contacting a cancer-
ous cell with the nanoparticle of claim 1 which has been 
conjugated with a ligand specific for a receptor expressed by 
the cancerous cell and wherein the drug is an anti-cancer 
drug. 
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20. The method of claim 19, further comprising tracking 
the nanoparticle by magnetic resonance imaging. 
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That which is claimed: 
1. A nanoparticle comprising: 
a metallic core; 
a polymeric coat surrounding said core and forming an 
outer periphery of said nanoparticle; 
a plurality of hydrophobic pockets formed by the poly-
meric coat; 
a plurality of carboxylic groups along an outer periphery of 
the polymeric coat and effective to conjugate with a 
predetermined targeting ligand which functionalizes the 
nanoparticle; 
a lipophilic fluorescent dye encapsulated in the plurality of 
hydrophobic pockets; and 
a drug encapsulated in the plurality of hydrophobic pock-
ets. 
21. The method of claim 19, further comprising tracking 
the nanoparticle by optical imaging relying on fluorescence. 
22. A method of treatment comprising contacting a dis-
40 eased cell with the nanoparticle of claim 1 which has been 
conjugated with a ligand specific for a receptor expressed by 
the diseased cell and wherein the drug is effective for treating 
the disease afflicting the cell. 
23. The method of claim 22, further comprising tracking 
45 the nanoparticle by magnetic resonance imaging. 
24. The method of claim 22, further comprising tracking 
the nanoparticle by optical imaging relying on fluorescence. 
25.A water based, step-wise method of making polyacrylic 
acid-coated iron oxide nanoparticles of claim 1, the method 
50 comprising: 
preparing an aqueous solution of iron salts by mixing 
FeC13 and FeC12 in dilute hydrochloric acid; 
2. The nanoparticle of claim 1, wherein the metallic core 55 
comprises a metallic oxide. 
preparing an alkaline solution by dissolving anm10nium 
hydroxide in deionized water purged with nitrogen gas; 
preparing a coating agent solution by dissolving poly-
acrylic acid in deionized water; 
3. The nanoparticle of claim 1, wherein the metallic core 
comprises superparamagnetic iron oxide. 
4. The nanoparticle of claim 1, wherein said polymeric coat 
comprises a biodegradable polymer. 
5. The nanoparticle of claim 1, wherein said polymeric coat 
comprises a matrix of polyacrylic acid. 
6. The nanoparticle of claim 1, wherein said polymeric coat 
comprises a biodegradable polymer effective for forming a 
plurality of hydrophobic pockets. 
7. The nanoparticle of claim 1, wherein folate groups are 
conjugated to the polymeric coat. 
60 
65 
reacting by mixing the iron salts solution with the alkaline 
solution while vigorously stirring the mixture to form a 
dark suspension of iron oxide nanoparticles; 
adding coating agent solution while stirring; 
separating the iron oxide nanoparticles from the suspen-
sion; 
washing the separated nanoparticles in water to minimize 
free polyacrylic acid and other unreacted reagents; 
purifying the washed nanoparticles through a magnetic 
column; and 
concentrating the purified nanoparticles. 
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26. A method of making polyacrylic acid-coated iron oxide 
nanoparticles of claim 1, the method comprising: 
reacting an acidic solution containing Fe+2 and Fe+3 ions 
with aqueous ammonium hydroxide to form a dark sus-
pension of iron oxide nanoparticles; 
mixing aqueous polyacrylic acid with the suspension of 
iron oxide nanoparticles while stirring for a time suffi-
18 
cient for the nanoparticles to become coated with the 
polyacrylic acid; 
separating coated iron oxide nanoparticles from the mix-
ture; and 
washing and concentrating the separated nanoparticles. 
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